Telcare Inc., the leader in mobile diabetes management solutions, has received CE Mark approval to market its cellular-enabled blood glucose meter (BGM), the first FDA-cleared mHealth glucose meter, in the European Union.
“We are excited to expand our reach of innovative, comprehensive diabetes management solutions to the European Union,” says Prof. Jonathan Javitt, Telcare’s co-founder, vice chairman, and CEO. “Diabetes will affect one in three people born after the year 2000 and has reached pandemic proportions world-wide. Our mobile platform unlocks the power of clinical data and creates multiple engagement points amongst those involved in an individual’s care to help minimize complications and improve health outcomes.”
More than 360 million people are currently living with diabetes, with this number expected to escalate to 552 million by 2030. Although the complications of diabetes can be prevented through daily monitoring and control of blood sugar, the World Health Organization estimates that 8,700 people are still dying daily from the disease. Telcare’s BGM offers an innovative approach to managing the impact of diabetes by liberating data from blood glucose readings and enabling the observation and evaluation of self-management behavior across an entire population.
By leveraging cellular-enabled mHealth tools to securely capture, store and share real-time clinical data, the BGM enables care teams to access the actionable data needed to identify at-risk individuals, make targeted and informed interventions and prevent complications. Evolving partnerships allow Telcare’s BGM to further assist and engage patients and their caregivers by building additional connections to biometric data. Telcare’s recent partnership with Qualcomm Life’s 2net cloud based platform allows the BGM to reliably deliver its data to integrated portals and databases designed to increase security and interoperability.